Study among cardiovascular patients confirms that PGx panel testing yields more savings and clinical impact than single gene testing though both are superior to non-personalized approaches to prescribing.
Results: Over 15 months, multi-gene testing was least costly and yielded more QALYs compared to both single gene and no
testing; total incremental costs were $1646 lower with incremental gains of 0.04 QALYs for multi-gene compared with single
gene and $11 368 lower with 0.17 QALY gains compared to no test. Base case analyses revealed multi gene was dominant
compared to both single gene and no test, as it demonstrated cost savings with increased QALYs.
Conclusions: For these patients, a multi-gene-guided strategy yields a favorable incremental cost-effectiveness ratio compared
to the other two treatment strategies. Pre-emptively ascertaining additional gene-drug pair information can inform clinical
and economic decision-making at the point of care.
